ReviewDiagnostics (Basel, Switzerland)2025
Endoscopic Diagnostics for IgG4-Related Pancreatobiliary Diseases: Current Modalities and Clinical Perspectives.
Review in Diagnostics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Type 1 autoimmune pancreatitis (AIP), IgG4-related sclerosing cholangitis (IgG4-SC), and IgG4-related cholecystitis are recognized as IgG4-related pancreatobiliary diseases. Endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasonography (EUS) are crucial diagnostic modalities for these conditions. In the diagnosis of AIP, EUS-guided tissue acquisition plays an important role in obtaining histological confirmation and excluding pancreatic cancer (PC). EUS, including contrast-enhanced harmonic imaging and elastography, is used to differentiate focal-type AIP from PC. Endoscopic retrograde pancreatography (ERP) is utilized to obtain a pancreatogram when it is challenging to distinguish AIP from pancreatic cancer. Duodenal papilla biopsy may serve as a supplementary tool, particularly in cases involving the pancreatic head. Cholangiographic classification is essential for differentiating IgG4-SC from PC, primary sclerosing cholangitis (PSC), and cholangiocarcinoma (CCA). ERCP is commonly performed for additional ERCP-related procedures. Intraductal ultrasonography (IDUS) is useful for distinguishing IgG4-SC from CCA or PSC. The primary role of bile duct biopsy is exclusion of malignant biliary strictures; EUS-guided tissue acquisition may also provide histological evidence of IgG4-SC. In the diagnosis of IgG4-related cholecystitis, EUS is helpful to differentiate it from gallbladder cancer. EUS-guided tissue acquisition can aid in confirming IgG4-related cholecystitis and excluding gallbladder cancer or xanthogranulomatous cholecystitis. Transpapillary gallbladder cytology or biopsy may also be considered. Overall, endoscopic modalities play a critical role in diagnosing IgG4-related pancreatobiliary diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.